Results 31 to 40 of about 635,953 (258)

The Usage of Influenza Vaccine to Prevent Seasonal Influenza during Pandemic COVID-19

Magna Medika, 2021
Influenza is an acute respiratory disease caused by influenza virus. Influenza can affect million people in every year and causing morbidity. Some of cases can be severe and need hospitalized, especially in elderly people.
Yelvi Levani, Ayu Lidya Paramita
doaj   +1 more source

Pseudotype-based neutralization assays for influenza: a systematic analysis [PDF]

, 2015
The use of vaccination against the influenza virus remains the most effective method of mitigating the significant morbidity and mortality caused by this virus.
Ferrara, Francesca, Keith eGrehan, Temperton, Nigel J., George William Carnell, Craig Peter Thompson, Francesca eFerrara, Nigel James Temperton, Grehan, Keith, Carnell, George W., Thompson, Craig P., Francesca Ferrara, Keith Grehan   +11 more
core   +1 more source

Cell culture-derived flu vaccine: Present and future

Human Vaccines & Immunotherapeutics, 2018
The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV ...
Alberto Pérez Rubio, Jose María Eiros
doaj   +1 more source

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. [PDF]

, 2009
Human infections with highly pathogenic avian influenza viruses of the H5N1 subtype, frequently reported since 2003, result in high morbidity and mortality.
Sutter, G. (Gerd), Sutter Gerd, Rimmelzwaan, Guus F., Osterhaus, A.D.M.E. (Albert), Yasemin Suezer, Gerrie de Mutsert, Suezer, Yasemin, Geert van Amerongen, Löwer, Johannes, Fouchier Ron A. M., Osterhaus, Albert D. M. E., Kreijtz, Joost H. C. M., Mutsert, Gerrie de, Fouchier, Ron A. M., Fouchier, R.A.M. (Ron), Guus F Rimmelzwaan, van den Brand Judith M. A., Löwer Johannes, Johannes Löwer, Kreijtz, J.H.C.M. (Joost), Suezer, Y., Judith M A van den Brand, Suezer Yasemin, Mutsert, G. (Gerrie) de, Amerongen, G. (Geert) van, Rimmelzwaan Guus F., Brand, J.M.A. (Judith) van den, Joost H C M Kreijtz, Sutter, Gerd, Schwantes, Astrid, de Mutsert Gerrie, Brand, Judith M. A. van den, Osterhaus Albert D. M. E., Schwantes Astrid, Scwantes, A. (Astrid), Ron A M Fouchier, van Amerongen Geert, Albert D M E Osterhaus, Gerd Sutter, Astrid Schwantes, Rimmelzwaan, G.F. (Guus), Kreijtz Joost H. C. M., Amerongen, Geert van, Löwer, J., Fouchier, Ron A.M.; id_orcid, Scwantes, Astrid, van Amerongen, Geert, van den Brand, Judith M.A., Osterhaus, Albert D.M.E., Kreijtz, Joost H.C.M., de Mutsert, Gerrie   +50 more
core   +1 more source

Evidence and guidance on vaccine safety and effectiveness in subpopulations [PDF]

, 2011
This dissertation examines post-licensing vaccine safety and effectiveness against two major respiratory diseases in specific subpopulations, with emphasis on safety.
Mak, Tippi
core   +1 more source

Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults

Vaccines
Background/Objectives: Waning immunity after primary COVID-19 vaccination supports evaluation of additional doses. HXP-GPOVac is an egg-based, inactivated Newcastle disease virus (NDV)-vectored vaccine expressing a prefusion-stabilized SARS-CoV-2 HexaPro
Prabda Praphasiri, Darunee Ditsungneon, Anusak Kerdsin, Sutthichai Nakphook, Jiraphut Kittiwatanachod, Kanlaya Sornwong, Suriya Naosri, Sarunpattori Khunarsa, Ponthip Wirachwong, Isariya Techatanawat, Piengthong Narakorn, Somchaiya Surichan, Jorge Flores, Laina D. Mercer, Christina S. Polyak, Bruce L. Innis, Rama Raghunandan, Chakrarat Pittayawonganon, Sopon Iamsirithaworn, Supakit Sirilak, Kriengkrai Prasert   +20 more
doaj   +1 more source

Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics

Frontiers in Microbiology, 2020
Influenza virus is a respiratory pathogen that can cause disease in humans, with symptoms ranging from mild to life-threatening. The vast majority of influenza virus infections in humans are observed during seasonal epidemics and occasional pandemics ...
Olivia A. Vogel, Balaji Manicassamy
doaj   +1 more source

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study [PDF]

, 2010
Objectives: To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.
Sheasby, E, Faust, S N, Okike, I, Miller, E., Casey, M., Walker, W T, Sheasby, E., Waight, P., Ladhani, S., Allen, R.J., Andrews, N, Eccleston, P.E., Faust, S.N., Oeser, C, John, T, Snape, MD, Pollard, AJ, Pollard, Andrew, Finn, A., Casey, M, Waddington, CS, Heath, PT, Heath, P.T., Collinson, AC, Eccleston, P E, Waddington, Claire S, Wilkins, S, Allen, R J, Faust, SN, Walker, W.T., Reiner, A, Ladhani, S, Collinson, A.C., Okike, I., Reiner, A., Waddington, Claire S., Miller, E, Andrews, N., Allen, RJ, Finn, A, Wilkins, S., Snape, M.D., Pollard, A.J., Eccleston, PE, Collinson, A C, Walker, WT, Heath, P T, Snape, M D, Hoschler, K., John, T., Hoschler, K, Waight, P, Oeser, C.   +52 more
core   +1 more source

Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins

Nature Communications
Conserved epitopes shared between virus subtypes are often subdominant, making it difficult to induce broadly reactive antibodies by immunization. Here, we generate a plasmid DNA mix vaccine that encodes protein heterodimers with sixteen different ...
Daniëla Maria Hinke, Ane Marie Anderson, Kirankumar Katta, Marlene Fyrstenberg Laursen, Demo Yemane Tesfaye, Ina Charlotta Werninghaus, Davide Angeletti, Gunnveig Grødeland, Bjarne Bogen, Ranveig Braathen   +9 more
doaj   +1 more source

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

Arthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin, Candace H. Feldman, Claire E. H. Barber, Gabriel Fabreau, Jake Jennings, Scott Patten, Cheryl Barnabe, Inflammatory Arthritis‐Specific ACSC Consensus Process Working Group   +7 more
wiley   +1 more source